Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    Pinealon

    Nootropics

    Status
    Preclinical, , not approved for human use
    Evidence

    Small human studies, graded on the Bioregulator Peptides (Khavinson Peptides) bench

    Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research.

    Reviewed

    01Overview

    What Pinealon is

    Pinealon was designed as a peptide analog of signaling molecules found in natural extracts of the pineal gland, specifically a class of bioactive compounds that Khavinson's group began isolating and characterizing in the late 1980s as "cytomedins" — short peptides extracted from specific animal tissues and claimed to carry tissue-specific regulatory signals back to the corresponding tissue type.

    Read the full overviewShow less

    The Khavinson framework is as follows: the pineal gland, like other endocrine and parenchymal organs, contains short regulatory peptides that are involved in cell differentiation, gene expression regulation, and tissue homeostasis. When these natural peptides are purified, sequenced, and synthetic analogs are produced (the short-peptide analogs being the most studied), the synthetic peptides retain the ability to influence the same tissue from which they were derived. Pinealon, as the pineal-derived tripeptide bioregulator, is claimed to act on neural tissue — particularly the brain — to support neuroprotection, cognitive function, circadian regulation, and protection against age-related neurodegeneration.

    A substantial body of Russian-language clinical and preclinical literature supports these claims, going back to the 1990s and continuing through 2026. The work has been led by Khavinson and his collaborators at the Mechnikov North-Western State Medical University in St Petersburg, published in Russian medical journals (Uspekhi Gerontologii, Bulletin of Experimental Biology and Medicine) and selected Western journals (Neuroendocrinology Letters, Biogerontology). Outside Russia, Pinealon is part of a broader group of short-peptide bioregulators that includes Epitalon, Thymogen, Thymalin, Vilon, Livagen, and others — each claimed to be organ-specific based on the source tissue of the original natural peptide extract.

    The Western biomedical community has given Khavinson's work a mixed reception. On the positive side, the theoretical framework — that short peptides could function as tissue-specific gene-expression modulators — is scientifically coherent, and a subset of the claims (particularly around Epitalon and telomere biology) has attracted genuine interest and some independent replication. On the skeptical side, the clinical datasets are predominantly Russian, the independent replication of the most dramatic outcomes is thin, the peptides have never been through standard Western regulatory approval processes, and the commercial availability in Russia through the "Cytogen" brand (Cytomed) and various gerontology clinics has driven a significant body-hacking export market without corresponding Western clinical validation.

    This entry takes the honest position that Pinealon — and the broader Russian short-peptide bioregulator category — represents a plausible mechanism of action with real Russian clinical use, limited Western replication, and a research-grade user experience outside Russia. It is not FDA-approved, not widely available through Western prescription pharmacies, and carries the full research-chemical status in most Western jurisdictions. Users engaging with Pinealon are effectively trusting Khavinson's lab and its affiliated clinical collaborators, without the standard Western regulatory and replication infrastructure.

    For readers exploring the Khavinson peptide space, see also Epitalon, Thymogen, Cartalax, Vilon, and related entries. For comparison with other short-peptide neuroprotective compounds, see Cerebrolysin (a larger neuropeptide preparation), Semax (Russian ACTH-derived peptide), and Selank.

    How it works

    The proposed mechanism of Pinealon is rooted in the Khavinson school's broader theory of short-peptide tissue-specific bioregulation. The full theory is worth understanding because it underlies all twelve Russian bioregulator compounds in this catalog.

    Read the full mechanismShow less

    The Khavinson short-peptide bioregulator theory:

    1. Tissue-specific short peptides exist endogenously. Cells in differentiated tissues produce and release short regulatory peptides (typically 2–4 amino acids) as signaling molecules. These peptides are claimed to be involved in tissue homeostasis, cell differentiation, and response to injury.

    2. Synthetic analogs retain tissue-specific activity. When the short peptide sequences are synthesized and administered exogenously, they are claimed to reach the corresponding tissue and modulate gene expression and cellular function in a tissue-selective manner.

    3. Direct gene-expression regulation. Khavinson's group has published work suggesting that short peptides can penetrate cell membranes (likely via peptide transporters or direct membrane permeability for small, charged molecules) and enter the nucleus, where they are proposed to bind specific DNA sequences at gene promoters or act on histones to modulate transcription. Papers in the 2000s from Khavinson and colleagues describe proposed binding of short peptides to specific DNA motifs using computational docking and NMR evidence.

    4. Cellular effects include:

    • Modulation of proliferation and differentiation in tissue-specific cell populations
    • Influence on telomerase activity (most famously for Epitalon, which is claimed to upregulate telomerase in human somatic cells)
    • Anti-inflammatory and antioxidant effects via downstream gene expression changes
    • Interactions with heat shock proteins and cellular stress response pathways

    Specific to Pinealon (Glu-Asp-Arg):

    • Pinealon was derived from a peptide extract of bovine pineal gland called "Epiphamine" or "pineal polypeptide extract," which was first characterized by Khavinson's group in the 1980s–1990s.
    • The Glu-Asp-Arg sequence was identified as biologically active within that extract and subsequently synthesized for research and clinical use.
    • Proposed targets include neuronal cells in the central nervous system, where Pinealon is claimed to:
    • Protect against oxidative stress (reducing reactive oxygen species and lipid peroxidation)
    • Support mitochondrial function in neurons
    • Upregulate neurotrophic factor expression (BDNF, NGF)
    • Support circadian regulation through pineal-related signaling
    • Protect against beta-amyloid and related neurotoxicity in models of Alzheimer's disease
    • Influence sleep regulation via melatonin-adjacent pathways

    Published mechanistic work:

    • [Khavinson and Kuznik (2011)] and related reviews from the Khavinson group describe the theoretical framework and cite multiple preclinical studies of Pinealon and related peptides.
    • [Arutjunyan et al. (2012)] reported protective effects of Pinealon against hypoxia-induced neuronal damage in cell culture models.
    • [Khavinson et al. (2012)] described effects of Pinealon on cognitive function in aged animals.
    • Russian-language publications in Uspekhi Gerontologii and Klinicheskaya Gerontologiya have extended these findings into clinical gerontology populations.

    The replication question:

    • Independent Western labs have confirmed some in-vitro cellular effects of short peptides (including a subset of the Khavinson peptides) but have not systematically replicated the dramatic clinical outcomes described in Russian literature.
    • The claim that short peptides directly bind DNA and act as transcription regulators is theoretically plausible but has not been conclusively demonstrated with the rigor that would be expected in a modern molecular biology framework.
    • The claim that Pinealon specifically reaches the brain after peripheral administration (subcutaneous or intranasal) in sufficient concentration to exert these effects has not been validated with modern pharmacokinetic methods in most target tissues.

    Honest mechanism summary:

    Pinealon is a short peptide with plausible but not fully validated mechanisms of neuroprotection, supported primarily by Khavinson-lab publications and limited independent replication. Cellular-level effects in simple in-vitro systems are reasonably well-documented; whole-organism pharmacokinetics and the most dramatic clinical claims are less well-supported. For readers with a strong mechanistic bias toward Western-validated pathways, this compound requires a higher trust threshold in Russian gerontology literature than a typical Western-approved drug.

    Benefits listed

    • Neuroprotection against oxidative and hypoxic stress (preclinical models)
    • Antioxidant support - reduced oxidative DNA damage in aged neurons (in vitro)
    • Cognitive and memory support in aging populations (small Russian clinical reports)
    • Reduced neuronal apoptosis and support of dendritic-tree integrity in cell models
    Show 1 moreShow less
    • Investigated for neuroprotection in Alzheimer's-model systems (preclinical)

    02Research

    Free with email

    What the research shows

    Graded on a research bench

    Reference pages that put Pinealon next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    Pinealon side effects and interactions

    Side effects

    Not in our record

    Our record lists no side effects for Pinealon. That means none are recorded here, not that there are none. The Research section has the written safety notes.

    Who should not use it

    Contraindications

    Absolute contraindications:

    • Pregnancy and lactation — no data on developmental effects
    • Pediatric use (under 18) — not studied; claimed to affect neural development
    • Known hypersensitivity to Pinealon or peptide products
    • Active seizure disorder without neurologic management
    • Active CNS infection (meningitis, encephalitis)
    • Recent severe head trauma (within 3 months)
    • Active hormone-sensitive cancer without oncologic evaluation (pineal/melatonin pathway involvement)
    • Severe mental illness (acute psychosis, suicidality) without psychiatric supervision
    • Users unable to access reputable source with verified purity
    • Users unable to perform or access safe injection technique
    Read all the contraindications and cautionsShow less

    Relative contraindications requiring cautious approach:

    • History of seizures or epilepsy
    • Active or recent psychiatric illness (depression, anxiety, bipolar) — theoretical CNS interactions
    • Autoimmune disease — Khavinson peptides claim immune-modulating effects; effects in active autoimmunity unclear
    • Organ transplant recipients on immunosuppression
    • Active systemic infection
    • Uncontrolled thyroid disease
    • Severe sleep disorder (especially parasomnias) — may be worsened by circadian-affecting peptides
    • Bleeding disorder or anticoagulation (injection site concerns)
    • Recent cardiac event
    • Advanced renal or hepatic disease

    Drug interactions (theoretical — limited formal data):

    • Melatonin — pineal-derived, theoretical additive or redundant effects; no documented adverse interaction
    • Antipsychotics and antidepressants — unclear; monitor for CNS effects
    • Mood stabilizers (lithium, valproate) — unclear interactions
    • Sleep medications (benzodiazepines, z-drugs, trazodone) — unclear interactions
    • Immunosuppressants — theoretical interaction with immune-modulating Khavinson peptide effects
    • Cognitive enhancers (cholinesterase inhibitors, memantine) — unclear interactions; generally considered compatible
    • Hormone therapies — unclear; theoretical pineal-hormone axis involvement
    • Anticoagulants and antiplatelets — injection-site bleeding risk; generally manageable

    Populations requiring specialist oversight:

    • Patients with neurodegenerative disease (Alzheimer's, Parkinson's) — may be appropriate candidates but require neurologic evaluation and monitoring
    • Patients with psychiatric comorbidities
    • Athletes in tested sport (verify Pinealon's current WADA status for their sport)
    • Patients with history of cancer, particularly pineal or CNS tumors
    • Patients with autoimmune disease

    Baseline evaluation before starting Pinealon:

    • Full history and physical examination
    • CBC, CMP, lipid panel, A1c, thyroid panel
    • Comprehensive hormonal panel if relevant to patient age and gender
    • Inflammatory markers (hs-CRP)
    • Consider cognitive testing baseline (if intended target is cognitive support)
    • Review of concurrent medications and supplements
    • Family history review (neurodegenerative disease, cancer, autoimmune)

    Monitoring during Pinealon use:

    • Subjective symptom tracking daily during cycles
    • Sleep quality and mood tracking
    • Injection site assessment
    • Any new neurologic symptoms — headache, vision change, motor change, cognitive decline — warrant immediate discontinuation and evaluation
    • Periodic (annual or semi-annual) repeat of baseline labs for trends

    When to discontinue immediately:

    • Any severe adverse reaction (anaphylaxis, severe allergic response)
    • Seizure or seizure-like event
    • New or worsening psychiatric symptoms
    • Persistent headache or neurologic symptoms
    • Injection site infection or systemic symptoms
    • Any concerning laboratory change
    • Pregnancy confirmed or planned

    Doping and sport considerations:

    • Pinealon is not currently on the WADA prohibited list (verify at time of use for specific sport rules)
    • However, research-chemical peptides carry contamination risk that can cause positive tests for other substances
    • Tested athletes should verify peptide purity or consider avoiding altogether

    Long-term safety considerations:

    • Multi-decade safety data on Pinealon specifically does not exist outside Russian clinical practice
    • Any user committing to long-term Khavinson peptide use should periodically reassess:
      • Whether biomarkers remain stable or improved
      • Whether new symptoms have emerged
      • Whether the research-chemical risk continues to be justified by the benefit
      • Whether their health has materially improved, plateaued, or declined

    Interaction with other Khavinson peptides:

    • Stacking multiple Khavinson peptides is common in the user community
    • No formal interaction data exists
    • Conservative approach: start with one peptide, establish response and tolerability, then gradually add others with attention to cumulative effects

    Special consideration — pineal health:

    • Pinealon's origin as a pineal peptide raises theoretical questions about effects on pineal function
    • In healthy individuals, this is not a known concern
    • In individuals with pineal pathology (cysts, tumors) or pineal surgical history, the compound should be avoided without specialist evaluation

    The contraindication summary: Pinealon has a reasonable safety profile in the available Russian clinical literature, but the evidence base is not strong enough to rule out rare or delayed adverse effects. The compound is best approached as a research-grade intervention with modest and pulsed dosing, reputable sourcing, appropriate monitoring, and willingness to discontinue if concerns emerge. For users whose medical history includes any of the absolute contraindications, Pinealon should not be used. For users with relative contraindications, specialist consultation is warranted.

    Interactions

    3 pairings in our record: 1 with a caution and 2 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • Melatonin

      Caution

      Both are associated with the pineal gland but act by different mechanisms; theoretical additive circadian/sleep effect - monitor for drowsiness, especially with evening dosing. Pinealon (EDR) is not established to raise endogenous melatonin.

    • Epithalon

      Synergistic

      Commonly stacked in Khavinson longevity protocols. Epithalon (AEDG) is the pineal/telomerase peptide; Pinealon (EDR) is the neuroprotective one - complementary targets rather than redundant.

    • DSIP

      Compatible

      Sometimes paired for sleep support - DSIP targets sleep architecture while Pinealon is taken in the morning. No formal interaction data; Pinealon's circadian effects are proposed, not established.

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    Pinealon dosage and protocols

    Dose range
    Subcutaneous (primary route): 2-10 mg/day, typically 3-5 mg, in pulsed 10-20 day cycles, 2-4 cycles/year. Intranasal: 150-800 mcg per nostril daily. Research use only; oral dosing is not recommended because the peptide is largely degraded by GI proteases.
    Dosing
    Once daily during a cycle (morning preferred); some advanced users split into AM + midday doses. Not dosed continuously year-round - cycles are pulsed.

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Dose, how often and how long
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes
    • Stacking notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    Pinealon prices

    3 listings from 2 vendors, opening in the Featured order.

    Pack prices
    $45.00 to $69.99
    Lowest per mg
    $3.00/mg
    Vendors
    2
    Listings
    3 (vial, nasal)

    Prices as the vendors list them, last recorded 7 September 2026.

    Size
    Form
    Sort
    Pinealon listings, in Featured order
    VendorProductPriceBuy

    Pinealon 20 mg

    vial, 1 vial

    In stock

    $3.00/mg

    $59.99

    Lowest per mg
    Buy Pinealon 20 mg at Disguised Alpha

    Pinealon Aerosol Spray

    nasal, 10 mL spray

    In stock

    $69.99

    No mg count

    Buy Pinealon Aerosol Spray at Disguised Alpha

    Pinealon 10mg

    vial, 1 vial

    In stock

    $4.50/mg

    $45.00

    Buy Pinealon 10mg at Ion Peptide
    Vendors selling Pinealon(2: trust score, certificates, payment, shipping)
    • Ion Peptide1 listing, from $45.00

      Trust Score 70/100, no certificate records on file, pays by card, crypto, ACH, ships to the US, international destinations

    • Disguised Alpha2 listings, from $59.99

      Trust Score 50/100, 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Price history(2 days with a recorded price)
    Review Pinealon

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Pinealon.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C15H26N6O8
    Molecular mass
    418.40 g/mol
    IUPAC name
    L-Glutamyl-L-aspartyl-L-arginine
    Amino acid sequence
    Glu-Asp-Arg (EDR)
    Half-life
    Not formally characterized in humans. Short regulatory peptides of this class are cleared from plasma within minutes; the Khavinson framework proposes durable downstream gene-expression effects that outlast the brief dosing window, which is the stated rationale for pulsed cycling rather than continuous dosing.
    View on PubChem

    08Questions

    Frequently asked questions

    Is Pinealon safe?

    Pinealon appears to be reasonably well-tolerated in the available Russian clinical literature and user-reported experience, with mild side effects being most common. However, the evidence base is limited compared to Western-approved drugs — most clinical studies are from a single research group (Khavinson's lab at the St Petersburg Institute of Bioregulation and Gerontology), published primarily in Russian-language journals, with limited independent Western replication. Long-term safety data over decades of use exists mainly within Russian clinical gerontology practice rather than from controlled Western studies. Users should treat it as a research-grade intervention with appropriate humility about what is and isn't known.

    What does Pinealon actually do?

    Pinealon is a synthetic tripeptide (Glu-Asp-Arg) derived from bovine pineal gland extract research, claimed to support neuroprotection, cognitive function, circadian regulation, and protection against age-related neurodegeneration. The proposed mechanism, per the Khavinson short-peptide bioregulator theory, is direct modulation of gene expression in neural tissue — though this mechanism has limited independent molecular biology validation. User-reported effects are typically subtle: slight improvements in mental clarity, sleep quality, and subjective energy during and after dosing cycles. Dramatic subjective effects are unusual and sometimes reflect placebo or product-quality variables.

    How is Pinealon related to Epitalon and other Khavinson peptides?

    Pinealon, Epitalon, Thymalin, Thymogen, Vilon, Livagen, Cartalax, and others are all products of the St Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. They share a common theoretical framework — short peptide bioregulators with claimed tissue-specific effects — and are typically produced and distributed through the same Russian clinical and commercial channels (Cytomed, Cytogen brand). Each peptide is claimed to target a different organ system: Pinealon (brain/pineal), Epitalon (pineal/telomeres), Thymalin/Thymogen (thymus/immunity), Cartalax (cartilage), Livagen (liver), and so on. Stacking multiple Khavinson peptides is common in the user community.

    Is Pinealon legal and how do I get it?

    Pinealon is not FDA-approved, not EMA-approved, and not available through Western prescription pharmacies for general use. In Russia, it is available through gerontology clinics and the Cytomed Cytogen brand. Outside Russia, it is typically obtained through research-chemical peptide suppliers, where legal status varies by jurisdiction — in most countries, personal research use occupies a gray area, while sale as a supplement or drug is not authorized. Users should understand customs risks and source from reputable research-peptide vendors with certificates of analysis. For related Russian peptides available through similar channels, see Semax and Selank.

    How do I use Pinealon — what's the typical protocol?

    The standard Khavinson-style protocol is pulsed rather than continuous: 10–20 day cycles of daily subcutaneous injection (2–5 mg per day), administered in the morning, with 60–90 day washouts between cycles. Most users run 2–4 cycles per year. An intranasal alternative at 150–500 mcg per nostril daily is sometimes used. Cycles can be run alone or in combination with other Khavinson peptides (most commonly paired with Epitalon). Begin at the lower end of the dose range, complete a full cycle before assessing, and increase only if response is inadequate. See the protocol sections above for beginner/intermediate/advanced details.

    Will Pinealon help with Alzheimer's or cognitive decline?

    Russian preclinical and clinical literature describes positive effects of Pinealon on cognitive function in aged animals and humans, including some studies in Alzheimer's-model systems and aging populations. These findings have not been systematically replicated in Western multi-center RCTs, and Pinealon is not an approved treatment for Alzheimer's disease in any jurisdiction. For individuals with diagnosed cognitive impairment or dementia, standard-of-care treatments (cholinesterase inhibitors, memantine, new anti-amyloid biologics where appropriate, lifestyle and cardiovascular optimization) should be the foundation. Pinealon may be a reasonable adjunct for users engaged with gerontology-informed protocols, but should not substitute for appropriate medical care.

    What's the difference between Pinealon and melatonin?

    Pinealon is a synthetic tripeptide (Glu-Asp-Arg); melatonin is a monoamine hormone (N-acetyl-5-methoxytryptamine). Both are associated with the pineal gland — Pinealon is derived from pineal peptide extracts while melatonin is the primary pineal hormone involved in circadian regulation. Pinealon's claimed mechanism is gene-expression regulation in neural tissue, while melatonin's mechanism is receptor binding (MT1 and MT2 melatonin receptors). The two can be used together in theory, and some users report additive benefits on sleep and circadian rhythm, but formal interaction data is limited. Melatonin is widely available, inexpensive, and well-characterized; Pinealon is a research-grade peptide with a narrower evidence base.

    Can Pinealon cause any sleep changes?

    Pinealon is claimed to have circadian-supportive effects and is most often used in the morning to align with its proposed pineal-axis mechanism. User reports include improved sleep quality in some individuals and mild insomnia (particularly if dosed in the evening) in others. Dosing timing matters: morning administration is the convention, and evening dosing should be avoided. Users with active sleep disorders (parasomnias, severe insomnia, sleep apnea) should approach Pinealon cautiously and prioritize resolving the underlying sleep issue through appropriate medical channels first.

    How does Pinealon compare to Semax or Selank?

    Semax and Selank are also Russian peptides with cognitive and mood-supporting effects, but they come from different research programs and have different mechanisms. Semax is an ACTH4-7 analog (MEHFPGP) developed for acute neuroprotection and cognitive enhancement; it has stronger Western research validation than Khavinson peptides and is more immediately noticeable in subjective effect. Selank is a neuroprotective anxiolytic peptide (TKPRPGP) derived from tuftsin; it has antianxiety and mild cognitive effects. Pinealon is from the Khavinson school with pulsed-dosing convention; its effects are more subtle and cumulative. Users often stack Pinealon cycles with daily Semax and Selank use for complementary effects.

    What should I actually do if I want to support cognitive aging?

    Start with the fundamentals that have the strongest evidence: regular aerobic exercise (150+ minutes per week), resistance training (2–3x per week), Mediterranean or MIND dietary pattern, 7–9 hours of quality sleep per night, social and intellectual engagement, stress management, and management of cardiovascular risk factors (blood pressure, lipids, glucose). Add evidence-based nutritional support: omega-3 EPA/DHA, vitamin D if deficient, adequate B12 and folate, creatine monohydrate (5 g/day, showing emerging cognitive benefit), and targeted supplementation based on labs. Consider approved cognitive pharmacotherapy if indicated (for diagnosed conditions). Research-grade interventions like Pinealon, Epitalon, Semax, and Selank are reasonable additions for users with the risk tolerance, monitoring capacity, and financial resources to engage with research-chemical peptides. For broader longevity and cognitive optimization strategies, see /stack and the full compound library.

    How many vendors sell Pinealon, and what does it cost per mg?

    2 of the vendors BodyHackGuide tracks list Pinealon (3 listings). Among BodyHackGuide's Pinealon listings recorded as in stock with a milligram count, the lowest price per milligram is $3.00/mg at Disguised Alpha and the median is $3.75/mg. The Pinealon prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Pinealon listing is dated 7 September 2026.

    Which vendors have third-party COAs for Pinealon on file at BodyHackGuide?

    BodyHackGuide holds 50 third-party certificate records for Pinealon, from BHG Labs. An editor has read 2 of BodyHackGuide's 50 certificate records for Pinealon and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's Pinealon certificate records are Freedom Diagnostics Testing and ILS Laboratories, and the newest test date on them is 6 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Related

    Articles on Pinealon

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free